These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

373 related articles for article (PubMed ID: 29718241)

  • 1. Cost-Effectiveness of Different Strategies for the Treatment of Moderate-to-Severe Ulcerative Colitis.
    Wu B; Wang Z; Zhang Q
    Inflamm Bowel Dis; 2018 Oct; 24(11):2291-2302. PubMed ID: 29718241
    [TBL] [Abstract][Full Text] [Related]  

  • 2. An economic evaluation of tofacitinib for the treatment of moderately-to-severely active ulcerative colitis: modeling the cost of treatment strategies in the United States.
    Milev S; DiBonaventura MD; Quon P; Wern Goh J; Bourret J; Peeples-Lamirande K; Soonasra A; Cappelleri JC; Quirk D
    J Med Econ; 2019 Sep; 22(9):859-868. PubMed ID: 31012362
    [No Abstract]   [Full Text] [Related]  

  • 3. Optimal treatment sequence for targeted immune modulators for the treatment of moderate to severe ulcerative colitis.
    Bloudek LM; Pandey R; Fazioli K; Ollendorf DA; Carlson JJ
    J Manag Care Spec Pharm; 2021 Aug; 27(8):1046-1055. PubMed ID: 34337994
    [No Abstract]   [Full Text] [Related]  

  • 4. Cost-Effectiveness of 5-Aminosalicylate Therapy in Combination With Biologics or Tofacitinib in the Treatment of Ulcerative Colitis.
    Shaffer SR; Huang E; Patel S; Rubin DT
    Am J Gastroenterol; 2021 Jan; 116(1):125-133. PubMed ID: 32947317
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Cost-effectiveness analysis of infliximab, adalimumab, golimumab, vedolizumab and tofacitinib for moderate to severe ulcerative colitis in Spain.
    Trigo-Vicente C; Gimeno-Ballester V; López-Del Val A
    Eur J Hosp Pharm; 2020 Nov; 27(6):355-360. PubMed ID: 33097619
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Cost-effectiveness of tofacitinib compared with infliximab, adalimumab, golimumab, vedolizumab and ustekinumab for the treatment of moderate to severe ulcerative colitis in Germany.
    Sardesai A; Dignass A; Quon P; Milev S; Cappelleri JC; Kisser A; Modesto I; Sharma PP
    J Med Econ; 2021; 24(1):279-290. PubMed ID: 33502905
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Cost-effectiveness analysis of infliximab, adalimumab, golimumab and vedolizumab for moderate to severe ulcerative colitis in Spain.
    Trigo-Vicente C; Gimeno-Ballester V; Montoiro-Allué R; López-Del Val A
    Expert Rev Pharmacoecon Outcomes Res; 2018 Jun; 18(3):321-329. PubMed ID: 29192530
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Identification of the Most Cost-effective Position of Vedolizumab Among the Available Biologic Drugs for the Treatment of Ulcerative Colitis.
    Scott FI; Luo M; Shah Y; Lasch K; Vajravelu RK; Mamtani R; Fennimore B; Gerich ME; Lewis JD
    J Crohns Colitis; 2020 Jun; 14(5):575-587. PubMed ID: 31901085
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Cost-Effectiveness Analysis of Vedolizumab Compared with Other Biologics in Anti-TNF-Naïve Patients with Moderate-to-Severe Ulcerative Colitis in Japan.
    Hernandez L; Kuwabara H; Shah A; Yamabe K; Burnett H; Fahrbach K; Koufopoulou M; Iwakiri R
    Pharmacoeconomics; 2020 Jan; 38(1):69-84. PubMed ID: 31552601
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Cost-effectiveness of vedolizumab compared with infliximab, adalimumab, and golimumab in patients with ulcerative colitis in the United Kingdom.
    Wilson MR; Bergman A; Chevrou-Severac H; Selby R; Smyth M; Kerrigan MC
    Eur J Health Econ; 2018 Mar; 19(2):229-240. PubMed ID: 28271250
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Cost-effectiveness of Tofacitinib in the Treatment of Moderate to Severe Rheumatoid Arthritis in South Korea.
    Lee MY; Park SK; Park SY; Byun JH; Lee SM; Ko SK; Lee EK
    Clin Ther; 2015 Aug; 37(8):1662-76.e2. PubMed ID: 26243076
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Cost-Effectiveness Analysis of Tofacitinib Compared with Biologics in Biologic-Naïve Patients with Moderate-to-Severe Ulcerative Colitis in Japan.
    Kobayashi T; Hoshi M; Yuasa A; Arai S; Ikeda M; Matsuda H; Kim SW; Hibi T
    Pharmacoeconomics; 2023 May; 41(5):589-604. PubMed ID: 36884164
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Efficacy of tofacitinib treatment in ulcerative colitis.
    Panés J; Gisbert JP
    Gastroenterol Hepatol; 2019; 42(6):403-412. PubMed ID: 31101342
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Continuation of Anti-TNF in Patients With Ulcerative Colitis in Remission Is Not Cost-effective Compared With Treatment Withdrawal: A Markov Model.
    Mahmoud R; van Lieshout C; Frederix GWJ; Jharap B; Oldenburg B
    J Crohns Colitis; 2021 May; 15(5):709-718. PubMed ID: 33125060
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Vedolizumab for the Treatment of Adults with Moderate-to-Severe Active Ulcerative Colitis: An Evidence Review Group Perspective of a NICE Single Technology Appraisal.
    Essat M; Tappenden P; Ren S; Bessey A; Archer R; Wong R; Lobo A; Hoque S
    Pharmacoeconomics; 2016 Mar; 34(3):245-57. PubMed ID: 26477040
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Systematic review with network meta-analysis: comparative assessment of tofacitinib and biological therapies for moderate-to-severe ulcerative colitis.
    Bonovas S; Lytras T; Nikolopoulos G; Peyrin-Biroulet L; Danese S
    Aliment Pharmacol Ther; 2018 Feb; 47(4):454-465. PubMed ID: 29205421
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A review of the cost-effectiveness of vedolizumab for treating moderate- to severely active ulcerative colitis.
    Tsai HH; Black C
    Expert Rev Pharmacoecon Outcomes Res; 2016 Dec; 16(6):679-683. PubMed ID: 27726457
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Systematic review with network meta-analysis: the impact of medical interventions for moderate-to-severe ulcerative colitis on health-related quality of life.
    Paschos P; Katsoula A; Salanti G; Giouleme O; Athanasiadou E; Tsapas A
    Aliment Pharmacol Ther; 2018 Dec; 48(11-12):1174-1185. PubMed ID: 30378141
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Infliximab, adalimumab and golimumab for treating moderately to severely active ulcerative colitis after the failure of conventional therapy (including a review of TA140 and TA262): clinical effectiveness systematic review and economic model.
    Archer R; Tappenden P; Ren S; Martyn-St James M; Harvey R; Basarir H; Stevens J; Carroll C; Cantrell A; Lobo A; Hoque S
    Health Technol Assess; 2016 May; 20(39):1-326. PubMed ID: 27220829
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Tofacitinib in the treatment of moderate-to-severe rheumatoid arthritis: a cost-effectiveness analysis compared with adalimumab in Taiwan.
    Chen DY; Hsu PN; Tang CH; Claxton L; Valluri S; Gerber RA
    J Med Econ; 2019 Aug; 22(8):777-787. PubMed ID: 30982378
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 19.